Anixa Biosciences presents breast cancer vaccine Phase 1 data showing all major endpoints met
ANIX•Anixa Biosciences said its breast cancer vaccine Phase 1 trial met all major endpoints; 74% of 35 patients dosed had a protocol-specified immune response, with no safety concerns reported. Phase 2 enrollment is the next milestone.
1. Trial results and finances
Anixa Biosciences completed its breast cancer vaccine Phase 1 trial, meeting all major endpoints; 74% of 35 patients dosed had a protocol-specified immune response, and no safety concerns were reported. The company said Phase 2 enrollment is the next milestone; its ovarian cancer CAR-T therapy lira-cel remains in Phase 1. Cash and short-term investments totaled $14 million as of July 31, 2026, with no debt, and total cash burn last fiscal year was $7 million.
